SCHEMBL546073

SCHEMBL546073

O=C(C=Cc1ccccc1)C=Cc1ccccc1.O=C(C=Cc1ccccc1)C=Cc1ccccc1.[Pd].[Pd]

nearest known ligand 0.95

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.95
CYP2C9 P11712 3/20 0.95
F3 P13726 3/20 0.95
CYP1A2 P05177 3/20 0.95
PLIN1 O60240 2/20 0.95
LMNA P02545 2/20 0.95
RECQL P46063 2/20 0.95
PLIN5 Q00G26 2/20 0.95
ABHD5 Q8WTS1 2/20 0.95
CYP2D6 P10635 2/20 0.95
ALDH1A1 P00352 2/20 0.95
SMN1; SMN2 Q16637 1/20 0.95
HDAC3 O15379 2/20 0.70
HDAC4 P56524 2/20 0.70
HDAC1 Q13547 2/20 0.70
HDAC2 Q92769 2/20 0.70
HDAC8 Q9BY41 2/20 0.70
HDAC6 Q9UBN7 2/20 0.70
TNKS O95271 1/20 0.70
HCAR2 Q8TDS4 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7512289 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL509571 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL1646390 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL5111 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL14832106 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL2438441 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL18039478 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL187662 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL21879664 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL2639578 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062361-A1 PROCESS FOR THE PREPARATION OF BIO-BASED OLEFINS FROM PRIMARY ALCOHOL BASF SE (DE) 2026-03-05 US claimed
CN-119930599-A Preparation process of high-purity azilsartan medoxomil 山东鲁宁药业有限公司 2025-05-06 CN claimed
CN-119731143-A Process for the preparation of biobased olefins from primary alcohols 巴斯夫欧洲公司 2025-03-28 CN claimed
CN-118271166-A Preparation method of 1, n-diol diacid ester compound 中国科学院上海有机化学研究所 2024-07-02 CN claimed
CN-118026804-A Preparation method of 1, 2-diaryl compound containing quaternary carbon center 中国科学技术大学 2024-05-14 CN claimed
CN-112469690-B Method for producing arylamines 默克专利有限公司 2024-04-16 CN claimed
US-20240101516-A1 SYNTHESIS OF POLYFLUORINATED ARYL AND HETEROARYL CARBOXAMIDES BASF SE (DE) 2024-03-28 US claimed
CN-117756950-A Bio-based carbonylation reagent and application thereof 东北林业大学 2024-03-26 CN claimed
EP-4281436-A1 SYNTHESIS OF POLYFLUORINATED ARYL AND HETEROARYL CARBOXAMIDES BASF SE (DE) 2023-11-29 EP claimed
CN-116947586-A Efficient preparation method of polysubstituted propenyl aromatic compound 大连理工大学 2023-10-27 CN claimed
EP-4132902-A1 PD-CATALYZED AMINATION OF FLUORINATED ARYL CHLORIDES BASF SE (DE) 2023-02-15 EP claimed
CN-115298160-A Pd-catalyzed amination of fluorinated aryl chlorides 巴斯夫欧洲公司 2022-11-04 CN claimed
WO-2022157106-A1 SYNTHESIS OF POLYFLUORINATED ARYL AND HETEROARYL CARBOXAMIDES BASF SE (DE) 2022-07-28 WO claimed
US-20220127251-A1 PROCESS FOR THE PRODUCTION OF ARYLAMINES MERCK PATENT GMBH (DE) 2022-04-28 US claimed
CN-114249682-A 1, 2-diol ester compound and preparation method thereof 中国科学院上海有机化学研究所 2022-03-29 CN claimed
CN-114031615-A Hydroxy-substituted pyridine oxazoline ligands and application thereof in hydrohalogenation reaction of olefin 中国科学院上海有机化学研究所 2022-02-11 CN claimed
US-8637449-B2 Processes for preparing protease inhibitors of hepatitis C virus MERCK SHARP & DOHME CORP. (US) 2014-01-28 US claimed
US-20120232247-A1 PROCESSES FOR PREPARING PROTEASE INHIBITORS OF HEPATITIS C VIRUS MERCK SHARP & DOHME CORP. 2012-09-13 US claimed
EP-2470189-A1 PROCESSES FOR PREPARING PROTEASE INHIBITORS OF HEPATITIS C VIRUS Merck Sharp & Dohme Corp. (US) 2012-07-04 EP claimed
WO-2011025849-A1 PROCESSES FOR PREPARING PROTEASE INHIBITORS OF HEPATITIS C VIRUS MERCK SHARP & DOHME CORP. (US) 2011-03-03 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127251-A1 PROCESS FOR THE PRODUCTION OF ARYLAMINES MAOB, TYR, INMT MAPT 445/4885CYP2C9 399/4885F3 1837/4885
US-20120232247-A1 PROCESSES FOR PREPARING PROTEASE INHIBITORS OF HEPATITIS C VIRUS RNASE1, TMPRSS15, HAVCR2 MAPT 4235/4885CYP2C9 129/4885F3 149/4885
US-20240101516-A1 SYNTHESIS OF POLYFLUORINATED ARYL AND HETEROARYL CARBOXAMIDES AADAC, PAICS, PARN MAPT 3567/4885CYP2C9 148/4885F3 210/4885
US-20260062361-A1 PROCESS FOR THE PREPARATION OF BIO-BASED OLEFINS FROM PRIMARY ALCOHOL ADH1C, ADH5, ADH1A MAPT 1518/4885CYP2C9 1179/4885F3 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.